Managing Tumour Marker for Breast Cancer with ECCT

Tumour Marker Dropped in just 3 weeks of ECCT

Malaysia, a 50s, female presented with a confirmed diagnosis of right breast cancer—Infiltrating Ductal Carcinoma, ER/PR positive, and HER2 negative—following the discovery of a hard lump in her right breast. Imaging revealed a suspicious mass with lymph node involvement, indicating an advanced stage of the disease.

The complexity of her case lay not only in the aggressive nature of infiltrating ductal carcinoma but present of body weakness and pain. She declines conventional treatments such as surgery, chemotherapy, and radiotherapy. Instead, she chose to proceed solely with ECCT.

Within three weeks of starting ECCT, the patient’s Tumour Marker for Breast Cancer demonstrated promising biochemical responses:

·       Ca 19.9 reduced from 22.3 reduced to 12.4

·       CEA dropped from 5.18 reduced to 3.07

·       Ca 15.3 decreased from 47.6 reduced to 41.6

These early changes, although not a substitute for imaging or histopathological confirmation, reflect a potential biological response to ECCT. The patient has shown stable overall well-being, reduced body pain and remains committed to her treatment plan.

While further clinical data and long-term monitoring are essential to fully understand the impact of ECCT on her case, this case illustrates the importance of respecting patient autonomy while pursuing safe, supportive, and individualized cancer care strategies. It also provides alternatives to conventional therapy—especially for patients seeking non-invasive options.